Healthcare
Compass Therapeutics Inc.(CMPX)
Live Price
Offline$2.02
-1.46% today
1Y Change
-21.09%
Window
Jun 27, 2025 โ Jun 18, 2026
- Market Cap
- $270.00M
- Revenue Growth
- -100.0%
- EPS Growth
- -16.7%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 27, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Compass Therapeutics Inc. (CMPX) is a Healthcare stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $2.02 and down 21.1% across the available one-year price window (Jun 27, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -16.7%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -16.7%, free cash flow -9.5% with operating margin 0.0% and ROIC -38.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CMPX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -16.7%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.1% | -2.5% | +2.5% |
2026 Mar 5, 2026 | +10.0% | -0.4% | -6.1% | -1.4% |
2025 Nov 5, 2025 | +42.9% | +4.7% | +28.3% | +45.0% |
Benchmark Edge
CMPX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CMPX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CMPX Max Drawdown
-75.04%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CMPX and SPY.
Company Overview
Compass Therapeutics Inc.
NASDAQ
Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody therapeutics, primarily in oncology. The company engages the immune system to treat multiple human diseases, with its scientific orientation centered on the relationship between angiogenesis, the immune system, and tumor growth. Its innovative platform features common light chain-focused antibody discovery, human display technology for antibody tuning, Stitchmabs, and highly modular, manufacturable bispecific antibody candidates. Key product candidates include CTX-009, CTX-471, CTX-10726, VEGF-A bispecifics, and CTX-8371, targeting various aspects of cancer immunotherapy. Compass Therapeutics Inc. operates within the health technology sector, specifically pharmaceuticals, advancing therapies that modulate immune responses against tumors. Founded in 2014 and headquartered in Boston, Massachusetts, the company plays a role in the competitive biopharmaceutical market by pioneering next-generation antibody-based treatments for unmet medical needs in oncology.
- Leadership
- Dr. Thomas J. Schuetz M.D., Ph.D.
- Employees
- 39
- Street Address
- 80 Guest Street, Suite 601
- Mailing
- Boston, MA, 02135
- Region
- Boston, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.9
Growth
- Revenue
- -100.0%
- EPS
- -16.7%
- Free Cash Flow
- -9.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -39.7%
- ROIC
- -38.3%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 19.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.